Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study

The Lancet

Volumn 387, Issue 10022, 2016, Pages 968-977

  Yao, James C ^a   Fazio, Nicola ^b   Singh, Simron ^c   Buzzoni, Roberto ^d   Carnaghi, Carlo ^e   Wolin, Edward ^f   Tomasek, Jiri ^g   Raderer, Markus ^h   Lahner, Harald ⁱ   Voi, Maurizio ^j   Pacaud, Lida Bubuteishvili ^j   Rouyrre, Nicolas ^j   Sachs, Carolin ^j   Valle, Juan W ^k   Fave, Gianfranco Delle ^l   Van Cutsem, Eric ^m   Tesselaar, Margot ⁿ   Shimada, Yasuhiro ^o   Oh, Do Youn ^p   Strosberg, Jonathan ^q   Kulke, Matthew H ^r   Pavel, Marianne E ^s   more..

^a UNIVERSITY OF TEXAS   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f UNIVERSITY OF KENTUCKY   (United States)

^g MASARYK UNIVERSITY   (Czech Republic)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j NOVARTIS PHARMA AG   (Switzerland)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁿ NETHERLANDS CANCER INSTITUTE   (Netherlands)

^o NATIONAL CANCER CENTER HOSPITAL   (Japan)

^p Seoul National University Hospital   (South Korea)

^q H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^r DANA FARBER CANCER INSTITUTE   (United States)

^s CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; PLACEBO; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER STAGING; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL TRACT NEUROENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; HUMAN; HYPERGLYCEMIA; INFECTION; INTERACTIVE VOICE RESPONSE SYSTEM; LUNG NEUROENDOCRINE TUMOR; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; NEUROENDOCRINE TUMORS; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; EVEROLIMUS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960112967     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00817-X     Document Type: Article

References (20)

1. JC Yao, M Hassan, A Phan et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 2008 3063 3072
2. MA Choti, S Bobiak, JR Strosberg et al. Prevalence of functional tumors in neuroendocrine carcinoma: An analysis from the NCCN NET database J Clin Oncol 30 2012 4126 (abstract).
3. J Yao, A Phan Optimising therapeutic options for patients with advanced pancreatic neuroendocrine tumours Eur Oncol Haematol 8 2012 217 223
4. A Rinke, HH Muller, C Schade-Brittinger et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group J Clin Oncol 27 2009 4656 4663
5. ME Caplin, M Pavel, P Ruszniewski Lanreotide in metastatic enteropancreatic neuroendocrine tumors N Engl J Med 371 2014 224 233
6. JC Yao, MH Shah, T Ito et al. Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
7. E Raymond, L Dahan, JL Raoul et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 2011 501 513
8. GM Blumenthal, P Cortazar, JJ Zhang et al. FDA approval summary: Sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors Oncologist 17 2012 1108 1113
9. N Fazio, D Granberg, A Grossman et al. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: Analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study Chest 143 2013 955 962
10. ME Pavel, B Wiedenmann, J Capdevila et al. RAMSETE: A single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in Europe J Clin Oncol 30 2012 4122 (abstr).
11. E Bajetta, L Catena, N Fazio et al. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study Cancer 120 2014 2457 2463
12. ME Pavel, JD Hainsworth, E Baudin et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study Lancet 378 2011 2005 2012
13. G Rindi, DS Klimstra, R Arnold et al. Nomenclature and classification of neuroendocrine neoplasm of the digestive system FT Bosman F Carniero RH Hruban ND Theise WHO classification of tumours of the digestive system 4th edn. 2010 International Agency for Research on Cancer Lyon 13 14
14. DS Klimstra, IR Modlin, D Coppola, RV Lloyd, S Suster The pathologic classification of neuroendocrine tumors Pancreas 39 2010 707 712
15. P Therasse, SG Arbuck, EA Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
16. L Fernandez-Cuesta, M Peifer, X Lu et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids Nat Commun 5 2014 3518
17. JM Francis, A Kiezun, AH Ramos et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors Nat Genet 45 2013 1483 1486
18. MS Banck, R Kanwar, AA Kulkarni et al. The genomic landscape of small intestine neuroendocrine tumors J Clin Invest 123 2013 2502 2508
19. JC Yao, AT Phan, DZ Chang et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study J Clin Oncol 26 2008 4311 4318
20. F Meric-Bernstam, A Akcakanat, H Chen et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors Clin Cancer Res 18 2012 1777 1789